Gyre Therapeutics

Historical price data

Gyre Therapeutics is advancing a pipeline of small molecule therapies designed to treat serious fibrotic and metabolic disorders with high unmet medical need. The company's lead program, FT011, represents a novel mechanism of action targeting fibrosis through selective inhibition of key pathways. With a valuation of approximately $640 million and a public listing, Gyre is positioned to advance its clinical programs through key data readouts. The company's approach focuses on diseases where fibrosis plays a central role in disease progression and organ dysfunction.

Small molecule platform targeting selective inhibition of fibrosis pathways through oral administration, with potential applications across multiple organ systems.

Total raised: $300M

Competes against large pharma companies (Boehringer Ingelheim, Eli Lilly, Bristol Myers Squibb) and biotech firms (Galecto, Pliant Therapeutics, FibroGen) in the fibrosis space. Differentiation through FT011's novel mechanism and oral administration route, with potential applications across multiple fibrotic diseases.